» Articles » PMID: 15951630

Case-control Study of the Muscular Compartments and Osseous Strength in Neurofibromatosis Type 1 Using Peripheral Quantitative Computed Tomography

Overview
Date 2005 Jun 14
PMID 15951630
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Skeletal anomalies are observed in neurofibromatosis type 1 (NF1), but the pathogenesis is unknown. Given that muscle mass is important in the development of the strength of bone, peripheral quantitative computed tomography (pQCT) was utilized to compare measurements of muscle compartments between NF1 individuals and controls. Forty individuals with NF1 (age 5-18 years) were evaluated. Cross-sectional measurements, at the 66% tibial site, were obtained using pQCT (XCT-2000, Stratec) and variables were compared to controls without NF1 ((age 5-18 years, N=380) using analysis-of-covariance controlling for age, height, Tanner stage, and gender. The NF1 cohort showed decreased total cross-sectional area [p<0.001], decreased muscle plus bone cross-sectional area [p<0.001], decreased muscle cross-sectional area [p<0.001], and decreased Stress Strain Index [p=0.010]. These data indicate that NF1 individuals have decreased muscle cross-sectional area and decreased bone strength than individuals without NF1.

Citing Articles

RASopathies - what they reveal about RAS/MAPK signaling in skeletal muscle development.

Rauen K, Tidyman W Dis Model Mech. 2024; 17(6).

PMID: 38847227 PMC: 11179721. DOI: 10.1242/dmm.050609.


Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1.

Gross A, Plotkin S, Watts N, Fisher M, Klesse L, Lessing A Clin Trials. 2023; 21(1):29-39.

PMID: 37772407 PMC: 10920397. DOI: 10.1177/17407745231201338.


The skeletal muscle phenotype of children with Neurofibromatosis Type 1 - A clinical perspective.

Chinoy A, Vassallo G, Burkitt Wright E, Eelloo J, West S, Hupton E J Musculoskelet Neuronal Interact. 2022; 22(1):70-78.

PMID: 35234161 PMC: 8919663.


Understanding the Biological Activities of Vitamin D in Type 1 Neurofibromatosis: New Insights into Disease Pathogenesis and Therapeutic Design.

Riccardi C, Perrone L, Napolitano F, Sampaolo S, Melone M Cancers (Basel). 2020; 12(10).

PMID: 33066259 PMC: 7602022. DOI: 10.3390/cancers12102965.


Skeletal muscle and motor deficits in Neurofibromatosis Type 1.

Summers M, Quinlan K, Payne J, Little D, North K, Schindeler A J Musculoskelet Neuronal Interact. 2015; 15(2):161-70.

PMID: 26032208 PMC: 5133719.